Somewhat Positive Press Coverage Somewhat Unlikely to Impact Affimed (AFMD) Stock Price

Media stories about Affimed (NASDAQ:AFMD) have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Affimed earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.612360759077 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Separately, Oppenheimer reissued a “hold” rating on shares of Affimed in a report on Friday, November 24th.

Shares of Affimed (AFMD) traded down $0.03 during trading on Wednesday, reaching $1.33. The company had a trading volume of 181,052 shares, compared to its average volume of 176,802. Affimed has a 52-week low of $1.15 and a 52-week high of $2.95. The stock has a market capitalization of $62.54, a P/E ratio of -1.70 and a beta of 3.48. The company has a debt-to-equity ratio of 0.14, a quick ratio of 6.39 and a current ratio of 6.43.

Affimed (NASDAQ:AFMD) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.21). Affimed had a negative return on equity of 72.94% and a negative net margin of 1,074.37%. equities analysts predict that Affimed will post -0.8 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/31/affimed-afmd-receiving-somewhat-favorable-press-coverage-analysis-shows.html.

Affimed Company Profile

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Insider Buying and Selling by Quarter for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply